Skip to main navigation Skip to search Skip to main content

Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

  • John K. Chan
  • , Mark F. Brady
  • , Richard T. Penson
  • , Helen Huang
  • , Michael J. Birrer
  • , Joan L. Walker
  • , Paul A. Disilvestro
  • , Stephen C. Rubin
  • , Lainie P. Martin
  • , Susan A. Davidson
  • , Warner K. Huh
  • , David M. O'Malley
  • , Matthew P. Boente
  • , Helen Michael
  • , Bradley J. Monk
  • Palo Alto Medical Foundation
  • Roswell Park Cancer Institute
  • Massachusetts General Hospital
  • University of Oklahoma
  • Women and Infants Hospital of Rhode Island
  • University of Pennsylvania
  • Fox Chase Cancer Center
  • University of Colorado Anschutz Medical Campus
  • University of Alabama at Birmingham
  • Ohio State University
  • Minnesota Oncology/Hematology-Oncology Service
  • Indiana University Bloomington
  • University of Arizona

Research output: Contribution to journalComment/debate

1 Scopus citations
Original languageEnglish
Pages (from-to)344-345
Number of pages2
JournalObstetrical and Gynecological Survey
Volume71
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer'. Together they form a unique fingerprint.

Cite this